• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Fresh Tracks Therapeutics Announces Hearing Date and Notice of Proposed Consent Judgement Regarding Dissolution of Company

    12/6/24 8:15:00 AM ET
    $FRTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $FRTX alert in real time by email

    BOULDER, Colo., Dec. 6, 2024 /PRNewswire/ -- Fresh Tracks Therapeutics, Inc. (OTC:FRTX) ("Fresh Tracks" or "the Company") announced today that a Scheduling Order has been issued by the Court of Chancery of the State of Delaware ("the Court") setting a hearing date of January 17, 2025, for the Court to consider entry of a Consent Judgment agreed to by the Company in the case of David R. McAvoy versus Fresh Tracks. If the Consent Judgment is approved by the Court, a custodian will be appointed for Fresh Tracks pursuant to 8 Del. C. § 226 with a directive to dissolve the Company and windup its affairs.

    In accordance with a Court-approved scheduling order, Fresh Tracks has sent or will send to each of its stockholders, as of the record date of November 20, 2024, by electronic mail and/or first class U.S. mail at their last-known addresses, full copies of the Notice of Proposed Consent Judgment ("the Notice"). Stockholders entitled to receive the Notice as of the record date are welcome to attend the Hearing, and full details are included within the Notice.

    Fresh Tracks Therapeutics, Inc.

    Investor Contact:

    Albert N. Marchio II

    Chief Executive Officer and Chief Financial Officer

    [email protected] 

    Cision View original content:https://www.prnewswire.com/news-releases/fresh-tracks-therapeutics-announces-hearing-date-and-notice-of-proposed-consent-judgement-regarding-dissolution-of-company-302324542.html

    SOURCE Fresh Tracks Therapeutics, Inc.

    Get the next $FRTX alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $FRTX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $FRTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Fresh Tracks Therapeutics Announces Dissolution, Initial Cash Distribution and Termination of Trading on the OTC Pink Market

      BOULDER, Colo., Feb. 25, 2025 /PRNewswire/ -- Fresh Tracks Therapeutics, Inc. (OTC:FRTX) ("Fresh Tracks" or the "Company") announced today an update on its previously announced, planned dissolution and its process for distributing cash to its stockholders. Fresh Tracks plans on filing a Certificate of Dissolution with the Delaware Secretary of State, with dissolution effective February 28, 2025. As previously disclosed, on January 15, 2025, the Court of Chancery of the State of Delaware appointed Albert N. Marchio II as the custodian of the Company (the "Custodian"). In connection with the dissolution, the Custodian has authorized an initial distribution of $0.96 per share to holders, as of

      2/25/25 4:05:00 PM ET
      $FRTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • /C O R R E C T I O N -- Fresh Tracks Therapeutics, Inc./

      In the news release, Fresh Tracks Therapeutics Announces Appointment of Custodian and Planned Distribution, issued 27-Jan-2025 by Fresh Tracks Therapeutics, Inc. over PR Newswire, we are advised by the company that the reference to "...first quarter of 2024" at the end of the first paragraph was incorrectly stated and should read "...first quarter of 2025". The complete, corrected release follows: Fresh Tracks Therapeutics Announces Appointment of Custodian and Planned Distribution BOULDER, Colo., Jan. 27, 2025 /PRNewswire/ -- Fresh Tracks Therapeutics, Inc. (OTC:FRTX) ("Fresh Tracks" or "the Company") announced today that the Court of Chancery of the State of Delaware ("the Court") has g

      1/27/25 4:05:00 PM ET
      $FRTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Fresh Tracks Therapeutics Announces Appointment of Custodian and Planned Distribution

      BOULDER, Colo., Jan. 27, 2025 /PRNewswire/ -- Fresh Tracks Therapeutics, Inc. (OTC:FRTX) ("Fresh Tracks" or "the Company") announced today that the Court of Chancery of the State of Delaware ("the Court") has granted the consent judgment agreed to by the Company in the case of David R. McAvoy versus Fresh Tracks, as a result of which the Court has appointed Albert N. Marchio II, Chief Executive Officer and Chief Financial Officer of Fresh Tracks, as the custodian of Fresh Tracks pursuant to 8 Del. C. § 226 with a directive to dissolve the Company and wind up its affairs. Fresh Tracks currently anticipates it will complete the dissolution and make a distribution of between $0.95 and $0.98 per

      1/27/25 4:05:00 PM ET
      $FRTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $FRTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Exploration Capital, Llc bought $381,170 worth of shares (405,500 units at $0.94) (SEC Form 4)

      4 - Fresh Tracks Therapeutics, Inc. (0000819050) (Issuer)

      6/11/24 9:37:53 PM ET
      $FRTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Exploration Capital, Llc bought $9,580 worth of shares (10,434 units at $0.92) (SEC Form 4)

      4 - Fresh Tracks Therapeutics, Inc. (0000819050) (Issuer)

      5/31/24 5:29:19 PM ET
      $FRTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Exploration Capital, Llc bought $20,821 worth of shares (22,889 units at $0.91) (SEC Form 4)

      4 - Fresh Tracks Therapeutics, Inc. (0000819050) (Issuer)

      5/23/24 5:29:14 PM ET
      $FRTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $FRTX
    Financials

    Live finance-specific insights

    See more
    • Fresh Tracks Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

      Reported positive topline results from SAD and MAD parts of Phase 1 study of lead DYRK1A inhibitor FRTX-02 in March 2023 Ongoing evaluation of strategic options to further develop FRTX-02 and maximize shareholder value Strengthened balance sheet with aggregate net proceeds of $6.6 million raised under an ATM program in March 2023 BOULDER, Colo., May 10, 2023 (GLOBE NEWSWIRE) -- Fresh Tracks Therapeutics, Inc. (the "Company" or "Fresh Tracks") (NASDAQ:FRTX), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases, today

      5/10/23 4:01:00 PM ET
      $FRTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Fresh Tracks Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

      Positive topline results from single and multiple ascending dose parts of the Phase 1 study of FRTX-02 support its continued development as a potential first-in-class, once-daily oral treatment for atopic dermatitis and/or other autoimmune diseases Continuing to evaluate strategic options to further develop FRTX-02 and maximize shareholder value Raised aggregate net proceeds of $6.6 million under ATM program in March 2023 BOULDER, Colo., March 30, 2023 (GLOBE NEWSWIRE) -- Fresh Tracks Therapeutics, Inc. (the "Company" or "Fresh Tracks") (NASDAQ:FRTX), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription the

      3/30/23 4:01:00 PM ET
      $FRTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $FRTX
    SEC Filings

    See more
    • SEC Form 15-12G filed by Fresh Tracks Therapeutics Inc.

      15-12G - Fresh Tracks Therapeutics, Inc. (0000819050) (Filer)

      3/18/24 5:05:32 PM ET
      $FRTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-K filed by Fresh Tracks Therapeutics Inc.

      10-K - Fresh Tracks Therapeutics, Inc. (0000819050) (Filer)

      3/15/24 4:09:01 PM ET
      $FRTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Fresh Tracks Therapeutics Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Financial Statements and Exhibits

      8-K - Fresh Tracks Therapeutics, Inc. (0000819050) (Filer)

      3/7/24 8:44:19 AM ET
      $FRTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $FRTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Exploration Capital, Llc bought $381,170 worth of shares (405,500 units at $0.94) (SEC Form 4)

      4 - Fresh Tracks Therapeutics, Inc. (0000819050) (Issuer)

      6/11/24 9:37:53 PM ET
      $FRTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Exploration Capital, Llc bought $9,580 worth of shares (10,434 units at $0.92) (SEC Form 4)

      4 - Fresh Tracks Therapeutics, Inc. (0000819050) (Issuer)

      5/31/24 5:29:19 PM ET
      $FRTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Exploration Capital, Llc bought $20,821 worth of shares (22,889 units at $0.91) (SEC Form 4)

      4 - Fresh Tracks Therapeutics, Inc. (0000819050) (Issuer)

      5/23/24 5:29:14 PM ET
      $FRTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $FRTX
    Leadership Updates

    Live Leadership Updates

    See more
    • /C O R R E C T I O N -- Fresh Tracks Therapeutics, Inc./

      In the news release, Fresh Tracks Therapeutics Announces Appointment of Custodian and Planned Distribution, issued 27-Jan-2025 by Fresh Tracks Therapeutics, Inc. over PR Newswire, we are advised by the company that the reference to "...first quarter of 2024" at the end of the first paragraph was incorrectly stated and should read "...first quarter of 2025". The complete, corrected release follows: Fresh Tracks Therapeutics Announces Appointment of Custodian and Planned Distribution BOULDER, Colo., Jan. 27, 2025 /PRNewswire/ -- Fresh Tracks Therapeutics, Inc. (OTC:FRTX) ("Fresh Tracks" or "the Company") announced today that the Court of Chancery of the State of Delaware ("the Court") has g

      1/27/25 4:05:00 PM ET
      $FRTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Fresh Tracks Therapeutics Announces Appointment of Custodian and Planned Distribution

      BOULDER, Colo., Jan. 27, 2025 /PRNewswire/ -- Fresh Tracks Therapeutics, Inc. (OTC:FRTX) ("Fresh Tracks" or "the Company") announced today that the Court of Chancery of the State of Delaware ("the Court") has granted the consent judgment agreed to by the Company in the case of David R. McAvoy versus Fresh Tracks, as a result of which the Court has appointed Albert N. Marchio II, Chief Executive Officer and Chief Financial Officer of Fresh Tracks, as the custodian of Fresh Tracks pursuant to 8 Del. C. § 226 with a directive to dissolve the Company and wind up its affairs. Fresh Tracks currently anticipates it will complete the dissolution and make a distribution of between $0.95 and $0.98 per

      1/27/25 4:05:00 PM ET
      $FRTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Fresh Tracks Therapeutics Announces Delaware Petition Filed Seeking Appointment of Custodian for Eventual Dissolution of Company

      BOULDER, Colo., June 17, 2024 (GLOBE NEWSWIRE) -- Fresh Tracks Therapeutics, Inc. (OTC:FRTX) ("Fresh Tracks" or the "Company") announced today that it has filed an Answer (the "Answer") to a Verified Petition for Appointment of a Custodian Pursuant to 8 Del. C. § 226 (the "Delaware Petition") that was filed with the Court of Chancery of the State of Delaware (the "Court") on May 17, 2024 by a stockholder and former General Counsel, Chief Compliance Officer, and Secretary of the Company, David R. McAvoy (the "Petitioner"). The Delaware Petition, to which the Answer outlines the Company is in overall agreement with, specifically requests that the Court issue an order appointing Albert N. Ma

      6/17/24 4:05:00 PM ET
      $FRTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $FRTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D filed by Fresh Tracks Therapeutics Inc.

      SC 13D - Fresh Tracks Therapeutics, Inc. (0000819050) (Subject)

      5/8/24 4:01:47 PM ET
      $FRTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Fresh Tracks Therapeutics Inc. (Amendment)

      SC 13G/A - Fresh Tracks Therapeutics, Inc. (0000819050) (Subject)

      1/17/24 8:37:18 PM ET
      $FRTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Fresh Tracks Therapeutics Inc. (Amendment)

      SC 13G/A - Fresh Tracks Therapeutics, Inc. (0000819050) (Subject)

      2/13/23 5:24:48 PM ET
      $FRTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care